Literature DB >> 32536336

SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018.

Hazel J Clothier1, Jock Lawrie2, Georgina Lewis3, Melissa Russell4, Nigel W Crawford5, Jim P Buttery6.   

Abstract

BACKGROUND: SAEFVIC is the Victorian surveillance system for adverse events following immunisation (AEFI). It enhances passive surveillance by also providing clinical support and education to vaccinees and immunisation providers. This report summarises surveillance, clinical and vaccine pharmacovigilance activities of SAEFVIC in 2018.
METHODS: A retrospective observational cohort study of AEFI reports received by SAEFVIC in 2018, compared with previous years since 2008. Data were categorised by vaccinee demographics of age, sex, pregnancy and Indigenous status, vaccines administered and AEFI reactions reported. Age cohorts were defined as infant (0-12 months); young child (1-4 years); school-aged (5-17 years); adult (18-64 years); and older person (65+ years). Proportional reporting ratios were calculated for signal investigation of serious adverse neurological events with all vaccines and with influenza vaccines. Clinical support services and educational activities are described.
RESULTS: SAEFVIC received 1730 AEFI reports (26.8 per 100,000 population), with 9.3% considered serious. Nineteen percent (n = 329) attended clinical review. Annual AEFI reporting trends increased for infants, children and older persons, but were stable for school-aged and adult cohorts. Females comprised 55% of all reports and over 80% of reports among adults. There were 17 reports of AEFI in pregnant women and 12 (0.7%) in persons identifying as Indigenous Australians. A possible signal regarding serious adverse neurological events (SANE) was detected, but was not supported by signal validation testing. A clinical investigation is ongoing. Two deaths were reported coincident to immunisation with no evidence of causal association.
CONCLUSION: SAEFVIC continues to provide robust AEFI surveillance supporting vaccine safety monitoring in Victoria and Australia, with new signal detection and validation methodologies strengthening capabilities. © Commonwealth of Australia CC BY-NC-ND.

Entities:  

Keywords:  adverse events; immunisation; pharmacovigilance; surveillance; vaccine safety

Mesh:

Year:  2020        PMID: 32536336     DOI: 10.33321/cdi.2020.44.46

Source DB:  PubMed          Journal:  Commun Dis Intell (2018)        ISSN: 2209-6051


  5 in total

1.  Shoulder injury related to vaccine administration (SIRVA): What do we know about its incidence and impact?

Authors:  Laura J Mackenzie; Mary-Jessimine A Bushell; Phillip Newman; Jaquelin A Bousie
Journal:  Explor Res Clin Soc Pharm       Date:  2022-09-26

2.  Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.

Authors:  Yu Hu; Xuejiao Pan; Linzhi Shen; Fuxing Chen; Ying Wang; Hui Liang; Yaping Chen; Huakun Lv
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 4.526

3.  Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.

Authors:  Xuejiao Pan; Huakun Lv; Fuxing Chen; Ying Wang; Hui Liang; Linzhi Shen; Yaping Chen; Yu Hu
Journal:  Hum Vaccin Immunother       Date:  2021-06-25       Impact factor: 4.526

4.  Victorian Specialist Immunisation Services (VicSIS) - bolstering adult clinics for COVID-19 vaccines.

Authors:  Sally F Gordon; Elise Virah Sawmy; Eleanor Duckworth; Michelle Wolthuizen; Hazel J Clothier; Malinda Chea; Naveen Tenneti; Ngaree Blow; Jim P Buttery; Joseph de Luca; Tony M Korman; Sara Barnes; Charlotte Slade; Callum Maggs; Michelle L Giles; Benjamin W Teh; Craig Aboltins; Katherine M Langan; Annaliese Van Diemen; Nigel W Crawford
Journal:  Hum Vaccin Immunother       Date:  2022-04-26       Impact factor: 4.526

5.  Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine.

Authors:  Manfred S Green; Victoria Peer; Avi Magid; Neta Hagani; Emilia Anis; Dorit Nitzan
Journal:  Vaccines (Basel)       Date:  2022-02-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.